Recent Updates
Recently added Catalysts
SNYR Positive Sentiment Score: 85/100

Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor to UAE & Turkey — Ignites Global Growth and New Revenue Streams

Key Takeaway: Synergy CHC Corp. (NASDAQ: SNYR) has expanded its international licensing agreement with Gravity Pharma to include Turkey alongside the UAE for the distribution of its FOCUSfactor brand. This strategic move has resulted in $2 million in upfront licensing revenue and opens additional revenue streams through performance-based royalties. Synergy aims to leverage high-growth markets without diluting ownership or shifting focus from its U.S. operations. The company also highlights the potential of the brain health market, which is expected to exceed $20 billion by 2030, indicating strong future growth prospects.

Market Sentiment Analysis

POSITIVE FACTORS

  • Expansion into Turkey and UAE presents significant growth opportunity.
  • Secured $2M in upfront licensing revenue.
  • Retains 100% ownership and global IP for FOCUSfactor brand.
  • The brain health market projected to exceed $20B by 2030.

Full Press Release Details

WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it has expanded its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor®. This move brings total upfront licensing revenue to $2 million, with additional performance-based royalties tied to product sales across both high-growth markets.
"This isn’t just an expansion—it’s execution," said Jack Ross, CEO of Synergy CHC Corp. “Adding Turkey alongside the United Arab Emirates (UAE), compounds our momentum and unlocks untapped growth in scalable, capital-efficient markets. We’re building brand equity globally without the overhead—exactly how growth should look in 2025.”
The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor® brand—including brain health supplements, cognitive beverages, and energy shots—without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP, with performance-based royalties driving long-term upside.
Key Highlights for Investors:
$2M in licensing secured
Additional revenue potential through royalties
Scalable, asset-light growth strategy
Brain health market expected to top $20B by 2030
With global demand for cognitive health solutions surging and strategic distribution partnerships now active, SNYR is well-positioned to capitalize on both brand strength and macro health trends. These developments follow key leadership hires from Coca-Cola’s global beverage team, reinforcing the Company’s commitment to accelerated growth and operational precision.
About Synergy CHC Corp.
Synergy CHC Corp. (NASDAQ: SNYR) is a next-generation consumer health and wellness company. Its flagship brands include FOCUSfactor®, a clinically tested brain health supplement, and Flat Tummy®, a lifestyle wellness brand for women. Synergy is executing a high-margin, global expansion strategy across functional health categories through capital-efficient partnerships.
Cody Slach, Greg Robles

Frequently Asked Questions

What is Synergy CHC Corp.'s recent licensing expansion?

Synergy CHC Corp. expanded its deal with Gravity Pharma to include Turkey and the UAE.

How much upfront licensing revenue did Synergy secure?

Synergy secured $2 million in upfront licensing revenue from this expansion.

What is FOCUSfactor®?

FOCUSfactor® is a clinically tested brain health supplement offered by Synergy.

What is the expected market size for brain health products?

The brain health market is projected to exceed $20 billion by 2030.

What strategy is Synergy employing for growth?

Synergy is using a scalable, asset-light growth strategy for its global expansion.

Last updated: Jun 18, 2025